B-cell lymphomas make up most (about 85%) of the non-Hodgkin lymphomas (NHL) in the United States. These types of lymphomas start in early forms of B lymphocytes (B cells). The most common types of ...
Eli Lilly's fast-growing blood cancer drug Jaypirca has bagged a new FDA approval as an earlier treatment for relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma ...
Back from ASH 2025, Dr Suchitra Sundaram reports on notable frontline CLL data. Time‑limited pirtobrutinib combined with venetoclax and obinutuzumab produced high rates of undetectable minimal ...
Credit: Tada Images / Shutterstock.com. At the American Society of Hematology (ASH) Annual Meeting, held on 6-9 December updated results from the global, multi-centre, open-label, Phase III BRUIN ...
Pirtobrutinib significantly improved progression-free survival in treatment-naive CLL/SLL patients, reducing disease progression risk by 80% compared to bendamustine plus rituximab. The trial ...
Jaypirca demonstrated non-inferiority to Imbruvica in treating CLL and SLL, with an 87% overall response rate compared to 78.6% for Imbruvica. As a non-covalent BTK inhibitor, Jaypirca offers ...
Fixed-duration venetoclax regimens showed non-inferior progression-free survival compared to continuous ibrutinib in CLL patients, offering treatment-free intervals. Safety profiles differed, with ...
Pirtobrutinib is now FDA-approved for relapsed/refractory CLL/SLL after prior covalent BTK inhibitor therapy, following its 2023 accelerated approval. The BRUIN-CLL-321 trial showed pirtobrutinib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback